Literature
Link to AI- and human-powered COVID-19 literature summaries. Stand on the shoulders of giants.
Literature
| Name | Description |
|---|---|
| BenchSci | Used AI to find experimental data and give reagent insights |
| Kaggle Inc | Dataset of 52,000 Covid-19 publications for AI analysis |
| ResearchGate | Covid-19 researchers, publications and community forum |
| World Economic Forum | Covid-19 strategic intelligence map |
| Coronavirus Resource Center | Covid-19 questions and answers |
| New England Journal of Medicine | Covid-19 articles, clinical resources and commentary |
| University of Oxford Literature Digest | Preprints on Covid-19 research |
| Washington University Medical School Covid-19 Lit. Review | Literature review compilation |
| COVID-19 Research Registry | Top COVID-19 research: timely, curated and vetted by experts |
| COVID-19 Research Guide | This guide provides resources for researching COVID-19 |
| Tulane Covid-19 Literature Digest | Daily Literature Digest |
| Coronavirus Knowledge Center | Cross-industry teams at Goodwin are helping clients fully understand and assess the ramifications of COVID-19 and navigate the potential effects of the outbreak on their businesses |
| BioCentury COVID-19 Resource Center | Free Covid-19 Information portal. |
| Opinion | How Long Will a Vaccine Really Take? | Experts say at least 18 months. Here’s how to shorten the timeline. |
| Gilead outlines plans to distribute COVID-19 drug worldwide | Gilead on Tuesday said it is negotiating with overseas drug manufacturers to license its coronavirus treatment remdesivir in an effort to speed global access. |
| WHO embraces plan for Covid-19 intellectual property pool | The World Health Organization embraced a proposal to create a voluntary pool to collect Covid-19 patent rights, regulatory test data, and other information. |
| Novavax aims to make one billion COVID-19 vaccine doses after buying plant | Novavax Inc is buying a manufacturing plant from privately held Serum Institute of India, the world's largest maker of vaccines by volume, as the U.S. company aims to produce 1 billion doses of its COVID-19 vaccine candidate next year. |
| Gilead: Short Course Remdesivir Tops Standard COVID-19 Tx | Modest efficacy, good safety in moderately ill patients in phase III study |
| Blood vessel attack could trigger coronavirus’ fatal ‘second phase’ | The virus had targeted their blood vessels. |
| MIT Press is announcing the launch of an open access journal that will publish reviews of preprints related to Covid-19, in an effort to quickly and authoritatively call out misinformation as well as highlight important, credible research. | |
| Data show panic and disorganization dominate the study of Covid-19 drugs | Data show panic and disorganization dominate the study of Covid-19 drugs. This analysis, conducted in partnership with Applied XL, found that one in every six trials was designed to study the malaria drugs hydroxychloroquine or chloroquine, which have been shown to have no benefit in hospitalized patients. |